FOLH1 and metastatic neoplasm: As ctDNA levels appear to be present in sufficient quantities for analysis in metastatic disease and the need for outcome risk stratifying and therapy predicting biomarkers is high in advanced CRPC, future studies should explore if the incorporation of ctDNA analysis into currently insufficient imaging-based selection strategies for PSMA-radioligand therapies allows for enhanced tumor biology profiling and thereby more personalized disease management.